Data Analysis: Assets by Therapeutic Class and Status & Developers with the Highest Number of Assets
Source:
Beacon Cell Therapy 6th December 2023
Exclusive Interview - Innate Killer Summit 2022
Neil Sheppard
Adjunct Associate Professor of Pathology &
Laboratory Medicine
University of Pennsylvania
Michael Curley
Director Cell Therapy Innovation
Takeda
Allen Feng
CEO
HebeCell Corp
Gregory Fiore
CEO
Exacis Biotherapeutics
Speaker Perspectives - Innate Killer Summit 2022
Austin Bigley
VP R&D
Indapta Therapeutics
Kimberly Schluns
Senior Director Research
Kite: A Gilead Company
Podcast - Innate Killer Summit 2023
Neil Sheppard
University of Pennsylvania
Center for Cellular Immunotherapies